1-2 of 2
Nina Orfali
Close
Sort by
Journal Articles

Venetoclax–based low intensity therapy in molecular failure of NPM1 -mutated AML

Clinical Trials & Observations
Carlos Jimenez-Chillon, Jad Othman, David Taussig, Carlos Jimenez-Vicente, Alexandra Martinez-Roca, Ing Soo Tiong, Manish Jain, James Aries, Seda Cakmak, Steven Knapper, Daniel Tuyet Kristensen, Vidhya Murthy, Joy Zacharoula Galani, Charlotte Kallmeyer, Loretta Ngu, David Veale, Simon Bolam, Nina Orfali, Anne Parker, Cara Manson, Jane Parker, Thomas Erblich, Deborah Richardson, Katya Mokretar, Nicola Potter, Ulrik Malthe Overgaard, Anne Stidsholt Roug, Andrew H. Wei, Jordi Esteve, Martin Jädersten, Nigel Russell, Richard Dillon
Journal: Blood Advances
Blood Adv (2024) 8 (2): 343–352.
https://doi.org/10.1182/bloodadvances.2023011106
Published: 2024
Includes: Supplemental data
Journal Articles

Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response

Clinical Trials & Observations
Ok-kyong Chaekal, Andromachi Scaradavou, Emeline Masson Frenet, Maria S. Albano, Melissa Cushing, Pinkal Desai, Ludy Dobrila, Usama Gergis, Danielle Guarneri, Jing-Mei Hsu, Sangmin Lee, Sebastian A. Mayer, Adrienne A. Phillips, Nina Orfali, Ellen K. Ritchie, Gail J. Roboz, Cynthia Romeo, Michael S. Samuel, Tsiporah Shore, Koen van Besien
Journal: Blood Advances
Blood Adv (2020) 4 (20): 5146–5156.
https://doi.org/10.1182/bloodadvances.2020002805
Published: 2020
Includes: Supplemental data